“You know, the Lilly data may be 2029, but it's kind of hard to look through this data and have a lot of confidence that Lp reductions pharmacologically are gonna make a material impact in cardiovascular outcomes.”
→ Read the source episode
Lilly publicly announces results from their Lp(a) cardiovascular outcomes trial in a press release or scientific presentation
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Belight Bio's tennleribans will receive FDA approval decision by February 12, 2027 for Stargardt disease.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.